Sun Pharma, an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients, has no paramount plans to enter the vaccine production craze as getting into the industry would require a different manufacturing set-up which is very different from what they have now as mentioned by a company official. “I think our preliminary assessment indicates that vaccines will require a dedicated manufacturing facility and it cannot be produced in a facility where we are making multiple other products,” Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said that their preliminary assessment has pointed out that the vaccine production will demand a dedicated manufacturing facility for production and it cannot be produced where their present products are being manufactured.
The company has now set its eye on biosimilars to fuel its future growth. Sun Pharmaceutical Industries Managing Director Dilip Shanghvi has said that “We are evaluating the development of some biosimilars which can be classified amongst the third wave of biosimilars,” when asked about the 10-year timeline for the company. Sun Pharma is now looking at products that have notable future patent expiry dates in order to be amongst the first firms to get initial approvals for this advancement.
